Rafal Kaminski
Chief Scientific Officer Angelini Pharma Inc
Seminars
Tuesday 8th December 2026
Innovating Antibody-Oligonucleotide Conjugates (AOCs) for Enhanced BBB Penetrance
With BBB-penetrating technologies at the forefront of Korean innovation, the next frontier lies in moving beyond antibody shuttles to explore receptor‑mediated transcytosis for delivering therapeutic oligonucleotides to the brain. In this interactive workshop, explore the possibilities of platforms such as ABL Bio’s Grabody-B being utilized to shuttle ASOs and siRNAs across the BBB, and ponder questions such as:
- What do we understand about the behaviour of oligonucleotides when conjugated to antibodies and how can we optimize the conjugation for effective delivery?
- How can we overcome the challenge of siRNA negative charge limiting intracellular delivery in the CNS?
- How can we maximize endosomal escape of IV-administered oligonucleotides in the CNS?
- What are the advantages of delivering oligonucleotides via RMT vs intrathecal administration?
Wednesday 9th December 2026
Panel Discussion | Exploring Next Generation RNA-Based Therapeutics to Access Undruggable CNS Targets with High Specificity & Target Engagement
1:30 pm
- Exploring the latest RNA editing approaches to target APOE, such as Rznomics’ trans-splicing-induced replacement of APOE4
- Discussing the potential of RNAi platforms to transverse the BBB and silence disease-causing genes in the brain
- Evaluating opportunities for ASOs, such as Sovargen’s SVG105, to achieve greater efficacy than conventional gene and small molecule therapies in epilepsies
- Evaluating novel exosome-based and lipid carrier platforms for CNS-targeted RNA therapeutics
Wednesday 9th December 2026
Spotlighting Angelini Pharma’s Focus on Brain Health: Novel Technologies & Modalities as Drivers of CNS Innovation
2:30 pm
- Exploring how to leverage novel modalities to target epilepsy, neurodevelopmental disorders, depression, neuromuscular diseases and more
- Referencing Angelini’s ASO-centered partnership with Sovargen
- Discussing novel formulation approaches including LNPs for enhanced CNS targeting
